Break out session Autoimmune Disorders 2024

Welcome to Autoimmune Disorders break out session Day 1

• 10.05-10.45 am: Invited speaker: Professor Ingrid Kockum, KI
  Tentative title: The role of genetics in disease activity in MS – Genetic epidemiology in MS. 
   
• 10.45-11.00 am: Selected abstract #1: The Impact of Adding Optical Coherence Tomography in MS Diagnostic criteria on Tumefactive Demyelination
  Dr Fiorella Guido,  MC
   
• 11.00 -11.15 am: Select abstract #2: , B cells repopulating after rituximab display increased activation at the single-cell transcriptomic level, despite the absence of clinical disease activity in MS
  MD. Starvaggi Cucuzza, KI
   
• 11.15-11.25 am: Continued discussions/short break 
   
• 11.25-11.55 am:  Invited speaker: Professor Eoin P. Flanagan, MC
  Antibody-associated CNS diseases associated with demyelination: Neuromyelitis optica spectrum disorder and MOG antibody-associated disease

 This session (Day 1, Part 2) will be hybrid (Zoom-link available on request) Rochester: 07.00-10.00 CDT

• 14.00-14.40 pm: Invited speaker: Professor Aaron Johnson, MC
  Immune-mediated Blood-Brain-Barrier disruption 
   
• 14.40-14.55 pm: Selected abstract #3: Dagur Ingi Jonsson , KI
  Epidemiology of Myelitis in Stockholm County 2008-2018 
   
• 14.55-15.10 pm: Selected abstract #4 PhD Begum Horuluoglu, KI
  Single cell RNA sequencing reveals increased tissue resident signature among expanded T cell clones in muscle of patients with inclusion body myositis 
   
• 15.10-15.25 pm:  Continued discussions/short break
   
• 15.25-15.55 pm: Invited speaker: Associate Professor Tobias Granberg, KI 
  Tentative title: Imaging in MS 
   
• 15.55-16.10 pm: Selected abstract #5 (Zoom): Dr Mark Keegan, MC
  Clinical Course of Critical Demyelinating Lesion-Associated Progressive Motor Impairment in Multiple Sclerosi
   
• 16.10-16.25 pm: Continued discussions/short break
   
• 16.25-16.40 pm: Selected abstract #6: MD, PhD Katharina Fink, KI
  The incidence of myelin oligodendrocyte glycoprotein antibody-associated disease in Stockholm, Sweden. 
   
• 16.40-17.00: Mingle and discussions about future and present collaborations.
   

Concluding remarks.

Welcome to Autoimmune Disorders break out session Day 2

• 09.10-09.50 am: Invited speaker: MD Veena Taneja, MC
  Gut as a sensor of autoreactivity and treatment for Rheumatoid Arthritis
   
• 09.50-10.05 am: Selected abstract #7: MD, PhD Sara Turcinov, KI
  Arthritis progressors have a decreased frequency of circulating autoreactive T cells during the at-risk phase of rheumatoid arthritis 
   
• 10.05-10.20 am: Selected abstract #8: MSc Marlene Schülein, KI
  Establishing a novel humanized mouse model to study anti-citrulline T cell reactivity
   
• 10.20-10.40 am:  Continued discussions/ short break
   
• 10.40-11.10 am:  Invited speaker: Associate Professor Leonid Padyukov, KI
  Tentative title: Genetics in rheumatic diseases – history and future 
   
• 11.10-11.25 am: Selected abstract #10: Dr Maxime Raffray, KI
  The 10 years care trajectories preceding a Rheumatoid Arthritis diagnosis
   
• 11.25-11.40 am: Selected abstract #9: MD, PhD Ioannis Parodis, KI
  IgG and IgA anti-LIN28A Outperform Anti-dsDNA and anti-Sm in Distinguishing SLE from Health and
  Other Autoimmune Diseases
   
• 11.40-12.00 am: Mingle and discussions about future and present collaborationsI

–Prof. Tony Hunter, Molecular and Cell Biology Laboratory, The Salk Institute, Introduced by Dr. Chris Adams (MC)

This session (Day 2, Part 2) will be hybrid (Zoom-link available on request) Rochester: 07.30-10.00 CDT 

• 14.30-15.10: Invited speaker: MD, Associate professor Katerina Chatzidionysiou, K
  Tentative title: Rheumatology/Immunology treatment 30 years
   
• 15.10-15.25: Selected abstract #11: MSc Jianyang Liu, KI
  Combined lipoprotein and lipidomic profile predict response to abatacept in early untreated rheumatoid arthritis
   
• 15.25-15.40: Selected abstract #12: MSc Sabreen Alabbasi, KI
  Janus kinase inhibitors enhance prostanoid biosynthesis in human whole blood in vitro: implications for cardiovascular side-effects and prevention strategies. 
   
• 15.40-15.55: Continued discussions/ short break
   
• 15.55-16.25: Invited speaker MC: (Zoom) MD Hu Zeng, MC
   Immune dysregulation in inflammatory arthritis immune related adverse event
   
• 16.25-16.40: Selected abstract #13: (Zoom) Dr. Minji Ai, MC
  Targeting mTORC2 to ameliorate systemic lupus erythematosus 
   
• 16.40-16.55: Selected abstract #14: (Zoom) Dr. Gabriel Figueroa, MC
  Impact of glucocorticoid dose on complete response, serious infections, and mortality during the initial therapy of lupus nephritis: A systematic review and meta‐analysis", 
   
• 16.55-17.00: Discussions and concluding remarks